Overview

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Gemcitabine